Immuno-oncology

The latest industry insight into combinations, improving patient responses and clinical progress of the development of immuno-oncology therapies.

Immuno-oncology
08/02/2018

The trial design for an immuno-oncology therapy can often be as complicated as the science itself! Designing effective clinical trials and translational models is a top priority for anyone in the immuno-oncology industry.

 

<...
Designing trials to improve clinical translation
Immuno-oncology
08/02/2018

So much has happened in the immuno-oncology industry since we spoke to Peter at IO Frontiers World 2017 in Miami. However, the balance between opportunities and challenges remains and we still need discussion and collaboration with regulators...

Striking the balance between regulatory opportunities and challenges
Immuno-oncology
22/01/2018

The pace of innovation across immuno-oncology biotechs is gaining speed and it can be challenging to keep track of scientific developments, new technologies and who is looking for their next big partnership.

 

The ann...

top 15 immuno-oncology biotechs 2018
Cell and Gene Therapy
11/01/2018

Successful development of advanced therapies relies on robust CRO partnerships but the industry is facing huge challenges with identifying and selecting the right partner with the right expertise.

 

This infographic provid...

CRO Selection for Advanced Therapies
Cell and Gene Therapy
08/03/2017

 

Bringing an advanced therapy to market is a technically demanding and high-risk undertaking in an ecosystem prone to innovative disruption and that necessitates complex supply chains and original reimbursement models th...

Quantitative understandings of risk in cell and gene therapies
Immuno-oncology
08/02/2017

Developing a fuller understanding of the brain’s circuitry represents a huge challenge, with an estimated 100 billion neurons in the brain and 1,000 trillion neuronal connections (10,000 per neuron) triggering thoughts and actions. Mc...

Immuno-oncology
07/02/2017

Several other recently reported positive randomised trials have started reversing the seemingly endless flow of failed cancer vaccine trials [1–4]. This has not been a complete reversal, however, with the recent report at ASCO that the Stimuvax ...

Immuno-oncology
03/02/2017

Several precision medicine clinical trials are underway using treatment algorithms to assign patients to specific targeted therapies based on tumour molecular. Examples of these trials include metastatic disease from all cancer types such as the S...

Immuno-oncology
08/01/2017

Dr de Fourgerolles: We are seeing a paradigm shift.  I think with the clinical results and the approval of anti-CTLA4, Yervoy® and now the anti-PD1 antibodies we are seeing real and significant clinical benefit for patie...